{"id":101274,"date":"2006-12-08T15:37:37","date_gmt":"2006-12-08T13:37:37","guid":{"rendered":"https:\/\/www.17047165566933.sritis.lt\/index.php\/2006\/12\/08\/moterims-skiepai-nuo-vezio\/"},"modified":"2006-12-08T15:37:37","modified_gmt":"2006-12-08T13:37:37","slug":"moterims-skiepai-nuo-vezio","status":"publish","type":"post","link":"https:\/\/www.santaka.info\/index.php\/2006\/12\/08\/moterims-skiepai-nuo-vezio\/","title":{"rendered":"Moterims \u2013 skiepai nuo v\u0117\u017eio"},"content":{"rendered":"<p><em><\/em><\/p>\n<p>Prie\u0161 por\u0105 savai\u010di\u0173 \u012f Lietuv\u0105 atgabenta vakcina, apsauganti nuo gimdos kaklelio v\u0117\u017eio.<br \/>\n<br \/>Tarptautin\u0117s farmacin\u0117s bendrov\u0117s \u201eMerck Sharp &#038; Dohme\u201c pagaminta vakcina \u201eSilgard\u201c apsaugo nuo \u017dPV 6, 11, 16 ir 18 tip\u0173, kurie sukelia 70 proc. gimdos kaklelio v\u0117\u017eio atvej\u0173 bei 90 proc. lytini\u0173 organ\u0173 karp\u0173.<br \/>\nKlinikiniai tyrimai, kuriuose dalyvavo 25 t\u016bkst. moter\u0173, parod\u0117, kad vakcina 100 proc. veiksmingumu u\u017ekirto keli\u0105 gimdos kaklelio v\u0117\u017eiui, taip pat prie\u0161v\u0117\u017einiams ir potencialiai prie\u0161v\u0117\u017einiams gimdos kaklelio pakitimams.<br \/>\n<br \/>Vadovaujantis medicinos ekspert\u0173 rekomendacijomis bei klinikini\u0173 tyrim\u0173 patvirtintais rezultatais, \u0161ia vakcina veiksmingiausia skiepytis 9\u201326 met\u0173 am\u017eiaus mergait\u0117ms, merginoms bei moterims.<br \/>\n<br \/>Lietuva pirmauja tarp ES \u0161ali\u0173 pagal mirtingum\u0105 nuo gimdos kaklelio v\u0117\u017eio. Kasmet Lietuvoje gimdos kaklelio v\u0117\u017eys yra nustatomas daugiau nei 500 moter\u0173. Pagal min\u0117tus rodiklius Lietuva pirmauja tarp ES \u0161ali\u0173 \u2013 kas savait\u0119 d\u0117l \u0161io sunkaus onkologinio susirgimo netenkame vidutini\u0161kai 5 moter\u0173. \u0160vedijoje nuo \u0161ios ligos toks mir\u0161tamumas buvo prie\u0161 60 met\u0173.<br \/>\n<br \/>Vilkavi\u0161kio ligonin\u0117s Aku\u0161erijos-ginekologijos skyriaus ved\u0117ja Skirma \u0160varcien\u0117 sak\u0117, jog Vilkavi\u0161kio medikai taip pat gali paskiepyti min\u0117ta vakcina, tik reik\u0117t\u0173 j\u0105 i\u0161 anksto u\u017esisakyti. Vakcina mokama, vienos doz\u0117s kaina \u2013 apie 400 lit\u0173. Skiepijama trimis vakcinos doz\u0117mis. Antroji vakcinos doz\u0117 skiriama pra\u0117jus 2 m\u0117nesiams po pirmosios, o tre\u010dioji \u2013 6 m\u0117nesiams po pirmosios. Skiepai \u0161virk\u0161\u010diami \u012f rankos raumenis. JAV \u0161ie skiepai jau \u012ftraukti \u012f vaikams privalom\u0173 skiep\u0173 s\u0105ra\u0161\u0105.<br \/>\n<br \/>Kita farmacijos bendrov\u0117 \u201eGlaxoSmithKline\u201c reklamuoja savo sukurt\u0105 vakcin\u0105 \u201eCervarix\u201c, kuri Lietuvoje tur\u0117t\u0173 pasirodyti ateinan\u010di\u0173 met\u0173 vasar\u0105. Vakcina \u201eCervarix\u201c nuo gimdos kaklelio v\u0117\u017eio apsaugos ne tik labai jaunas, bet ir vyresnes \u2013 26\u201355 met\u0173 \u2013 moteris. Vakcina jau paskiepyta ir stebima daugiau nei 30 000 moter\u0173 visame pasaulyje. \u201eCervarix\u201c neutralizuoja visus keturis pagrindinius onkogeninius \u017dPV tipus \u2013 16, 18, 31 ir 45, kurie lemia apie 80 proc. susirgim\u0173 gimdos kaklelio v\u0117\u017eiu. <\/p>\n<p>\u201eSantakos\u201c inform.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prie\u0161 por\u0105 savai\u010di\u0173 \u012f Lietuv\u0105 atgabenta vakcina, apsauganti nuo gimdos kaklelio v\u0117\u017eio. Tarptautin\u0117s farmacin\u0117s bendrov\u0117s \u201eMerck Sharp &#038; Dohme\u201c pagaminta vakcina \u201eSilgard\u201c apsaugo nuo \u017dPV 6, 11, 16 ir 18&#8230; <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pmpro_default_level":"","jetpack_post_was_ever_published":false,"_FSMCFIC_featured_image_caption":"NULL \/ NULL","_FSMCFIC_featured_image_nocaption":"","_FSMCFIC_featured_image_hide":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-101274","post","type-post","status-publish","format-standard","hentry","category-uncategorized","pmpro-has-access"],"featured_image_urls":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","post-thumbnail":"","visualnews_post_thumb":"","woocommerce_thumbnail":"","woocommerce_single":"","woocommerce_gallery_thumbnail":""},"author_info":{"info":["admin"]},"category_info":"<a href=\"https:\/\/www.santaka.info\/index.php\/category\/uncategorized\/\" rel=\"category tag\">Be kategorijos<\/a>","tag_info":"Be kategorijos","comment_count":"0","jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/posts\/101274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/comments?post=101274"}],"version-history":[{"count":0,"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/posts\/101274\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/media?parent=101274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/categories?post=101274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.santaka.info\/index.php\/wp-json\/wp\/v2\/tags?post=101274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}